Rationale
Schizotypal personality disorder (SPD) is associated with working memory (WM)
impairments that are similar to those observed in schizophrenia. Imaging studies have
suggested that schizophrenia is associated with alterations in dopamine D1-receptor
availability in the prefrontal cortex (PFC) that may be related to the WM impairments
that characterize this disorder.
Objectives
To characterize prefrontal D1-receptor availability and its relation to WM
performance in SPD.
Methods
We used positron emission tomography (PET) and the radiotracer
[11C]NNC112 with 18 unmedicated SPD and 21 healthy-control
participants; as an index of D1-receptor availability, binding-potential (BP) measures
(BPF, BPND, and BPP) were calculated for prefrontal
and striatal subregions. To assess WM, SPD participants completed the 2-back and Paced
Auditory Serial Addition Test (PASAT).
Results
There were no significant group differences in PFC BP. BPF and
BPP in the medial PFC were significantly negatively related to PASAT
performance (rs=-0.551,
p=.022 and rs=-0.488,
p=.047, respectively), but BP was not related to 2-back
performance.
Conclusions
In contrast to what has been found in schizophrenia, SPD was not associated
with significant prefrontal D1-receptor alterations. Similar to previous schizophrenia
findings, however, higher prefrontal D1-receptor availability was associated with poorer
WM performance (as measured by the PASAT) in SPD. These findings suggest that
schizophrenia and SPD may share a common pathophysiological feature related to
prefrontal dopamine functioning that contributes to WM dysfunction, but that in SPD,
alterations in D1 may occur only in a subset of individuals and/or to an extent that is
minor relative to what occurs in schizophrenia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.